Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Blood (2024) 144 (Supplement 1): 4.

https://doi.org/10.1182/blood-2024-208913

Published: 2024

Journal Articles

Bendamustine Is Less Toxic Than Fludarabine-Cyclophosphamide-Based Lymphodepletion before CD28-Costimulated CART19 through Reduced Inflammatory Cytokines

Blood (2023) 142 (Supplement 1): 4483.

https://doi.org/10.1182/blood-2023-182234

Published: 2023

Journal Articles

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

Adam D. Cohen, Wei-Ting Hwang, Sandra Susanibar-Adaniya, Dan T. Vogl, Alfred L. Garfall, Adam Waxman, Danielle Zubka, Chau Nguyen, Cynthia Diaczynsky, Marco Ruella, Michael C. Milone, Edward A. Stadtmauer

Blood (2023) 142 (Supplement 1): 3389.

https://doi.org/10.1182/blood-2023-187409

Published: 2023

Journal Articles

Ontogeny of the Alloimmune Anti-Canine Factor VIII Inhibitor Response in Severe Hemophilia Α Dogs

Robert Chen, Bhavya S Doshi, Timothy C. Nichols, Michael C. Milone, Ben J. Samelson-Jones, Valder R Arruda, Vijay Bhoj, Don L. Siegel

Blood (2021) 138 (Supplement 1): 3173.

https://doi.org/10.1182/blood-2021-149215

Published: 2021

Journal Articles

Perfecting CAR Engraftment to a Tee (Cell) through Characterization of Single Cell Transcriptome Product and Understanding Neurotoxicity

Wesley Wilson, Fei Miao, Alfred L Garfall, Dexiu Bu, Elena J Orlando, Jennifer L Brogdon, Iulian Pruteanu-Malinici, Adam D Cohen, Michael C. Milone

Blood (2021) 138 (Supplement 1): 1707.

https://doi.org/10.1182/blood-2021-151785

Published: 2021

Journal Articles

Human Orthogonal IL-2/IL-2Rβ As a Tunable Approach to Enhance CD19-Speific CAR-T Cell Antitumor Activity

Qian Zhang, MDPhD, Morgan Hresko, Michael Jacob Hollander, Lora Picton, Leon Su, Selene Nunez-Cruz, Jonathan T Sockolosky, K.Christopher Garcia, PhD, Michael C. Milone

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-140463

Published: 2020

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1863.

https://doi.org/10.1182/blood-2019-131515

Published: 2019

Journal Articles

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Meng Wang, BS, Iulian Pruteanu, PhD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Lifeng Tian, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Jennifer Brogdon, PhD, Megan Davis, PhD, Vanessa E. Gonzalez, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Michael C. Milone, Edward A. Stadtmauer, MD FACP, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 1909.

https://doi.org/10.1182/blood-2019-122396

Published: 2019

Journal Articles

Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy

Eduardo Huarte, PhD, Roddy S O'Connor, PhD, Melissa Parker, Taisheng Huang, Michael C. Milone, Paul Smith

Blood (2019) 134 (Supplement_1): 1934.

https://doi.org/10.1182/blood-2019-128288

Published: 2019

Journal Articles

Simple, 1-Day Manufacturing of Quiescent Chimeric Antigen Receptor T Cells for Adoptive Immunotherapy

Saba Ghassemi, PhD, Roddy S O'Connor, PhD, Selene Nunez-cruz, PhD, Jai Patel, John Leferovich, Michael C. Milone

Blood (2019) 134 (Supplement_1): 4436.

https://doi.org/10.1182/blood-2019-131147

Published: 2019

Journal Articles

4-1BB-Costimulated CAR-Mediated Non-Canonical NF-Kb Signaling Enhances CAR T Cell Survival and Suppresses Bim Expression

Michael C. Milone, MD PhD, Roddy OConnor, PhD, Michael May, PhD, Steven Albelda, MD, Benjamin Philipson, BA

Blood (2018) 132 (Supplement 1): 3713.

https://doi.org/10.1182/blood-2018-99-119522

Published: 2018

Journal Articles

Optimized FVIII-Domain-Based Chimeric Antigen Receptors to Specifically Target FVIII Inhibitor-Producing B Cells in Hemophilia a

Vijay Bhoj, MD PhD, Lucy Li, Benjamin J. Samelson-Jones, MD PhD, Bhavya S Doshi, MD, Christoph Ellebrecht, MD, Aimee Payne, MD PhD, Valder R Arruda, MD PhD, Michael C. Milone, MD PhD

Blood (2018) 132 (Supplement 1): 2196.

https://doi.org/10.1182/blood-2018-99-120031

Published: 2018

Journal Articles

PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells

Luca Bernabei, Alfred L. Garfall, MD, J. Joseph Melenhorst, PhD, Simon F Lacey, PhD BS, Edward A. Stadtmauer, MD FACP, Dan T. Vogl, MD, Vanessa Gonzalez, Gabriela Plesa, MD, Regina M Young, PhD, Adam Waxman, MD, Bruce L Levine, PhD, Carl H June, MD, Michael C. Milone, MD PhD, Adam D. Cohen, MD

Blood (2018) 132 (Supplement 1): 1973.

https://doi.org/10.1182/blood-2018-99-119514

Published: 2018

Journal Articles

Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Adam D. Cohen, MD, J. Joseph Melenhorst, PhD, Alfred L. Garfall, MD, Simon F Lacey, PhD BS, Megan Davis, PhD, Dan T. Vogl, MD, Lifeng Tian, PhD, Vanessa Gonzalez, Iulian Pruteanu, PhD, Anne Marie Nelson, Gabriela Plesa, MD, Adam Waxman, MD, Regina M Young, PhD, Bruce L Levine, PhD, Carl H June, MD, Edward A. Stadtmauer, MD FACP, Michael C. Milone, MD PhD

Blood (2018) 132 (Supplement 1): 1974.

https://doi.org/10.1182/blood-2018-99-119665

Published: 2018

Journal Articles

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma

Ehren Dancy, MD, Alfred L. Garfall, MD, Adam D. Cohen, MD, Joseph A Fraietta, PhD, Megan Davis, PhD, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Edward A. Stadtmauer, MD FACP, Dan T. Vogl, MD, Adam Waxman, MD, Aaron P. Rapoport, MD, Michael C. Milone, MD PhD, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2018) 132 (Supplement 1): 1886.

https://doi.org/10.1182/blood-2018-99-115319

Published: 2018

Journal Articles

False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy

Theodore W. Laetsch, Shannon L. Maude, Michael C. Milone, Kara L. Davis, Joerg Krueger, Ana Maria Cardenas, Lamis K. Eldjerou, Christopher H. Keir, Patricia A. Wood, Stephan A. Grupp

Blood (2018) 131 (23): 2596–2598.

https://doi.org/10.1182/blood-2017-12-822940

Published: 2018

Journal Articles

Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)

Blood (2017) 130 (Supplement 1): 505.

https://doi.org/10.1182/blood.V130.Suppl_1.505.505

Published: 2017

Journal Articles

B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study

Blood (2016) 128 (22): 1147.

https://doi.org/10.1182/blood.V128.22.1147.1147

Published: 2016

Journal Articles

Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control

Saba Ghassemi, PhD, Patel Prachi, John Scholler, Selene Nunez-Cruz, PhD, David M. Barrett, MD PhD, Felipe Bedoya, PhD, Joseph A. Fraietta, PhD, Simon Francis Lacey, PhD BS, Bruce L Levine, PhD, Stephen A. Grupp, MD PhD, Carl H June, MD, Michael C. Milone, MD PhD, J. Joseph Melenhorst, PhD

Blood (2016) 128 (22): 4549.

https://doi.org/10.1182/blood.V128.22.4549.4549

Published: 2016

NARROW

Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Bendamustine Is Less Toxic Than Fludarabine-Cyclophosphamide-Based Lymphodepletion before CD28-Costimulated CART19 through Reduced Inflammatory Cytokines

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

Ontogeny of the Alloimmune Anti-Canine Factor VIII Inhibitor Response in Severe Hemophilia Α Dogs

Perfecting CAR Engraftment to a Tee (Cell) through Characterization of Single Cell Transcriptome Product and Understanding Neurotoxicity

Human Orthogonal IL-2/IL-2Rβ As a Tunable Approach to Enhance CD19-Speific CAR-T Cell Antitumor Activity

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy

Simple, 1-Day Manufacturing of Quiescent Chimeric Antigen Receptor T Cells for Adoptive Immunotherapy

4-1BB-Costimulated CAR-Mediated Non-Canonical NF-Kb Signaling Enhances CAR T Cell Survival and Suppresses Bim Expression

Optimized FVIII-Domain-Based Chimeric Antigen Receptors to Specifically Target FVIII Inhibitor-Producing B Cells in Hemophilia a

PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells

Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma

False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy

Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)

B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study

Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only